Publications in collaboration with researchers from Clínica Universitaria de Navarra (44)

2025

  1. Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

    European Journal of Cancer, Vol. 217

2024

  1. Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models

    JCI Insight, Vol. 9, Núm. 18

  2. Differential Impact of Valproic Acid on SLC5A8, SLC12A2, SLC12A5, CDH1, and CDH2 Expression in Adult Glioblastoma Cells

    Biomedicines, Vol. 12, Núm. 7

  3. Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile

    Neuro-oncology, Vol. 26, Núm. 9, pp. 1723-1737

  4. The emerging field of viroimmunotherapy for pediatric brain tumors

    Neuro-oncology, Vol. 26, Núm. 11, pp. 1981-1993

  5. The heterogeneous sensitivity of pediatric brain tumors to different oncolytic viruses is predicted by unique gene expression profiles

    Molecular Therapy Oncology, Vol. 32, Núm. 2

  6. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models

    Neuro-Oncology, Vol. 26, Núm. 8, pp. 1509-1525

2022

  1. Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas

    JCI Insight, Vol. 7, Núm. 7

  2. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma

    New England Journal of Medicine, Vol. 386, Núm. 26, pp. 2471-2481

  3. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies

    Neuro-oncology, Vol. 24, Núm. 9, pp. 1408-1422

2021

  1. Clinical value of NGS genomic studies for clinical management of pediatric and young adult bone sarcomas

    Cancers, Vol. 13, Núm. 21

  2. Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 4

  3. Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT/RT and CNS-PNET

    Clinical Cancer Research, Vol. 27, Núm. 6, pp. 1807-1820

  4. Hitchhiking to brain tumours: stem cell delivery of oncolytic viruses

    The Lancet Oncology

2020

  1. Somatic and germline analysis of a familial Rothmund–Thomson syndrome in two siblings with osteosarcoma

    npj Genomic Medicine, Vol. 5, Núm. 1

2019

  1. Destress and do not suppress: Targeting adrenergic signaling in tumor immunosuppression

    Journal of Clinical Investigation, Vol. 129, Núm. 12, pp. 5086-5088

  2. Localized treatment with oncolytic adenovirus delta-24-RGDOX induces systemic immunity against disseminated subcutaneous and intracranial melanomas

    Clinical Cancer Research, Vol. 25, Núm. 22, pp. 6801-6814

  3. Oncolytic adenovirus Delta-24-RGD induces a widespread glioma proteotype remodeling during autophagy

    Journal of Proteomics, Vol. 194, pp. 168-178

  4. The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Basic and Translational Advances in Glioblastoma

    BioMed Research International